Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 7/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.39 |
| ▸ | CETP | P11597 | 4/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129360 | 0.91 | CETP (0.47) | ALDH1A1TACR1SERPINE1GPBAR1CETP | |
| SCHEMBL129291 | 0.83 | PDK2 (0.41) | TACR1GPBAR1CETP | |
| SCHEMBL3823681 | 0.82 | SERPINE1 (0.41) | TACR1SERPINE1GPBAR1 | |
| SCHEMBL130203 | 0.73 | CETP (0.45) | PTPN2PTPN1PTPN6CETP | |
| SCHEMBL3829886 | 0.71 | CETP (0.45) | TACR1SERPINE1GPBAR1CETP | |
| SCHEMBL20129855 | 0.69 | CYP19A1 (0.47) | ALDH1A1SERPINE1PTGDR2 | |
| SCHEMBL3332143 | 0.68 | GAA (0.51) | — | |
| SCHEMBL7639892 | 0.68 | TACR1 (0.51) | ALDH1A1TACR1PTPN2PTPN1PTPN6 | |
| SCHEMBL6647004 | 0.66 | PRKCA (0.62) | ALDH1A1 | |
| SCHEMBL4877059 | 0.65 | MEN1 (0.39) | ALDH1A1SERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979331-B1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-8076364-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | NAKAMURA YOSHINORI | 2011-04-21 | — | — | US | disclosed |
| US-7906517-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | CETP, MTTP, APOB | ALDH1A1 3054/4885TACR1 3049/4885PTPN2 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.